The FAB group has reviewed 32 cases of promyelocytic leukemia and variant forms. By utilizing published criteria the ability to make a correct diagnosis by morphology with molecular genetic confirmation and to eliminate cases that did not have the PML/RAR␣ rearrangement was excellent. Leukemia (2000) 14, 1197-1200.
Introduction
Over 20 years ago the French-American-British (FAB) Cooperative Group published a detailed description of hypergranular promyelocytic (M3) leukemia. 1 The leukemic cells were described as: '(a) abnormal promyelocytes with a characteristic pattern of heavy granulations; (b) the nucleus varies greatly in shape and is often reniform or bilobed; (c) the cytoplasm of most of the cells is completely occupied by closely packed or even coalescent large granules staining bright pink, red or purple by Romanowsky dyes. In some cells the cytoplasm is filled with fine dust-like granules. Characteristic cells containing bundles of Auer rods (faggots) randomly distributed in the cytoplasm are almost invariably present in the bone marrow and sometimes in the peripheral blood. The cytoplasm of the cells which contain faggots is often clear and pale staining but may also contain azurophil granules' (Figure 1) .
Although the vast majority of cases of M3 fit this description a variant form accounting for 15-20% has been recognized [2] [3] [4] characterized by minimal rather than excessive granulation. The nuclei are bilobed, multilobulated or reniform and because of the paucity of granules may be confused with promonocytes. However, at least a few of the cells in the marrow aspirates have the typical features of abnormal promyelocytes ( Figure 2 ).
The cytochemistry of both forms of M3 show characteristic strong positivity for peroxidase (Figure 3 ) or Sudan Black B and for chloroacetate esterase. The bundles of Auer rods are recognized easily with the latter stains but not the former.
A unique chromosomal translocation that defines M3 is t(15;17) (q22;q12). 5 This translocation results in the fusion of the promyelocytic leukemia gene 'PML' and the retinoic acid receptor (RAR␣) gene. 6 With the use of conventional cytogenetics the t(15;17) can be detected in the vast majority of cases with M3 at the time of diagnosis. 7 Probably all cases can be detected by either the application of fluorescence in situ hybridization (FISH) 8, 9 or by molecular analysis. 10, 11 In addition Gallagher and coworkers 12 have described molecular variants of the fusion product: the long or L form (PML exon 6 to RAR␣ exon 2; the variable or V form) exon 6 coding nucleotides to RAR␣ exon 2 and the short or S form (PML exon 3 to RAR␣ exon 2). Neither of the two major types (S,L) have prognostic significance although the microgranular variety of M3 is more commonly seen with the S form. 13 In 1993, Chen and coworkers 14 described a fusion product between a novel zinc finger gene and the retinoic acid receptor with t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. Licht and coworkers 15 reported on five additional 'M3-like' cases with morphology 'in a small morphologic spectrum with features intermediate between M2 and classical M3 AML'. The gene fusion product was referred to as PLZF-RAR␣. None of the patients responded to all-trans retinoic acid (ATRA). The published photomicrographs reveal myeloblasts with heavy granulations but no faggot cells or nuclear features of M3, although the report mentions 'faggots' and or Auer rods in three out of four cases.
In 1996 16 a second novel translocation t(11;17)(q13;q21) was identified in a survey of patients diagnosed morphologically as 'APL' (FAB M3). The fusion product described was NuMA/RAR␣. Finally a different translocation, t(5;17) (q32;q12) associated with the NPM-RAR␣ fusion gene product was described. 17 In a subsequent paper Redner et al 18 demonstrated maturation to neutrophils in cell culture treated with ATRA.
To further clarify this important observation, members of the FAB Co-operative Group held a workshop in June 1996 in London, UK. In addition to the FAB members, Dr Cheryl Willman, Professor of Pathology at the University of New Mexico Cancer Center and chair of the Leukemia Biology Committee of the Southwest Oncology Group (SWOG) attended.
Materials and methods
Cases of both classical 'M3' and those with different cytogenetic findings but resembling 'M3' were assembled by the workshop participants. Romanowsky-stained slides were examined after being coded. Without any clinical or laboratory information each of the seven participants completed a worksheet that included the presence or absence of: (1) granules; (2) coarse or large granules, fine or thick granules, many or few, faggots; (3) maturation, presence or absence of Pelger Huët anomaly, irregular nuclei or bilobed nuclei, hyperbaso- philic cytoplasm, degree of peroxidase activity (% of cells and intensity), presence or absence of chloroacetate esterase positivity with multiple rod-like structures. Based on a 'global' assessment each morphologist was asked to record: (1) Classical M3; (2) M3 variant; (3) Not M3. Thirty-two cases were reviewed. Agreement was defined as at least five of the seven participants providing the same diagnosis.
Results
There were 21 cases in which all seven participants agreed that the morphologic diagnosis was FAB M3 (either hypergranular form or variant form 2, 3 ). Of these cases 19 had t (15;17) . Of the remaining two cases one was positive by PCR (fusion product PML/RAR␣ and one case had a t (11;17) .
Of the 11 cases where there was no concordance among the reviewers (eg less than 5/7 agreement) where the diagnosis made was either FAB M1 or M2 or M3, the following cytogenetics/molecular genetics were found: (1) Three were negative for t(15;17) by cytogenetics and PCR techniques; (2) Three were t(11;17) ( Figure 4) ; (3) Five had single abnormalities as follows: one inv(16); one PML/RAR␣ (nonreciprocal); one t(1;16); one t(1;10); and one with t(1:17).
Neither Auer rods or bundles of single rods were recorded in these cases but a single round to oval nucleus and pseudoPelger-like mature granulocytes was often seen.
Morphologic concordance (MC) was compared to the cytogenetic and molecular rearrangements (CMR) for t (15;17) by applying the Fisher's exact test (see Table 1 ). The difference was highly significant (P = Ͻ0.0001). Table 1 Correlation of morphologic concordance (MC) with cytogenetic/molecular rearrangements (CMR) 
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Discussion
In the treatment strategies developed recently for patients with acute promyelocytic leukemia (APL) the detection of the t(15;17) or the PML-RAR␣ rearrangement is critical. In the absence of either the likelihood of a response to ATRA is remote. 19, 20 On a morphologic basis an incorrect diagnosis of APL is made less frequently than in other FAB subtypes, 21 but is well documented. 22 The t(11;17) translocation and other rearrangements including t(5;17) may present with a morphology that can be confused with classical M3 (t (15;17) ). Grimwade and coworkers 23 identified seven of 100 patients who were admitted to a Medical Research Council trial of ATRA in APL who did not have cytogenetic/molecular evidence of APL. Six of the seven patients were rejected by a 'blinded' panel for morphologically typical APL (three normal; one +8; one t(6;12); one (x;6). Although no long term remission duration or survival information was available the complete remission rate for the seven patients without t(15;17) was 57% compared to 83% for the presence of t(15;17) PML/RAR␣ or both.
Tallman et al 20 in a recently published trial of ATRA found that all 10 cases of PML-RAR␣ negative 'APL' admitted to the study failed to respond to ATRA. An excellent review on the RAR␣ fusion protein of APL has been published recently. 24 In the present study, a morphologic panel utilized the precise criteria published previously by the FAB Cooperative Group for both the typical 1 and variant form. 2 Of the four cases of t(11;17)(q23,a21) three were identified correctly as not having classical APL morphology.
Our results demonstrate that by following the criteria published previously, the likelihood of making a correct morphological diagnosis is extremely high. In contrast, none of the cases, lacking t(15;17)were identified as having the typical morphology of APL. Similar results have been presented recently by another international group. 25 Recently Pollock and co-workers 26 have demonstrated in a transgenic mouse model that the co-expression of RAR␣-PML with PML-RAR␣ significantly increased the percentage of acute promyelocytic leukemia development in the 'PR/RP' animals. This resulted in a higher percentage of immature cells in the mouse spleens. The correlation of this observation to the arrested 'promyelocytic' cell in human APL is striking.
Although molecular genetics can be carried out much more rapidly than conventional cytogenetics it is reasonable to start all suspected M3 cases on ATRA until confirmation is obtained. Morphology continues to be the primary diagnostic method and therefore improving its precision should help investigators to eliminate cases that would not benefit from ATRA.
